Telix Pharmaceuticals Limited American Depositary Shares (TLX) Stock Price, Quote & AI Analysis

Live TLX stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Telix Pharmaceuticals Limited American Depositary Shares.

TradeVae provides AI-driven analysis and real-time market intelligence for Telix Pharmaceuticals Limited American Depositary Shares (TLX), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.

T
TLX
Telix Pharmaceuticals Limited American Depositary Shares
real-time
$0.00 +0.00 (+0.00%)
Open
10.940000
High
10.960000
Low
10.800000
Volume
186,285
VWAP
-
Market Cap
$2,594,114,758.75
52W Range
$6.28 - $12.48
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Telix Pharmaceuticals Limited American Depositary Shares's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Telix Pharmaceuticals Limited American Depositary Shares Overview

Company information

Company Overview

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

Company Details
Market Cap
$3.69B
Shares Outstanding
339,784,000
Weighted Shares Outstanding
334,724,485
CEO
Christian P. Behrenbruch
Employees
554
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and indicators

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Telix Pharmaceuticals Limited American Depositary Shares Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...